South Korean bioventures have experienced a harsh financing environment in 2023 stemming from economic depression, high interest rates and a general deterioration in investor sentiment.
Korean Biotech IPOs Fall In Tough Environment But Brighter Outlook Ahead?
Several Smaller Offerings Launched In '23
Several innovation-based Korean bioventures, including GI Innovation, S.Biomedics and Curocell, have managed to launch IPOs in 2023 despite prolonged depressed market sentiment and tougher stock exchange rules.
